SAN DIEGO, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation…
LONDON, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell…
Company has enrolled 10 of the targeted 16 patients in the trial Anticipates interim data in mid-2022 and topline data…
- Approved for all eligible indications of the reference biological product, Humira® (adalimumab) - - YUSIMRY is Coherus' second FDA-approved…
Company retains iiiNTENT SAAS artificial intelligence marketing service for Tollovid® and Tollovid Daily™ 3CL protease inhibitor dietary supplement products NEW…
re+PLAY(TM) re+PLAY(TM) - a Harrington Wellness product re+PLAY is a sports performance and recovery-focused brand founded by NBA veteran Al…
CELEBRATION, Fla., Dec. 20, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery and…
VBL is among only 9% of companies across industries selected by the EIC Accelerator Funds to be used for clinical…
JI XING to Develop and CommercializeNovel Cardiac Myosin Activator in Patients with Heart Failure Cytokinetics to Receive $70 Million in…
-- Clinical development of the MYC repressor APTO-253 will be discontinued -- -- Company will focus on advancing kinome inhibitor…